San Diego-based venture capital firm Domain Associates and its Russian partner, Rusnano, have put part of their $760M, late stage investment fund to work, investing a total of $93M in funding in three portfolio companies of Domain. The two said Wednesday that they have invested $21M in Marinus Pharmaceuticals, $20.6M in Lithera, $51M in Regado Biosciences as part of the funding effort. The two firms said that, to date, they have invested more than $130M of their fund. Domain Associates put together the unique joint investment fund in March, tapping funding from none other than the Russian government for those investment funds. Marinus is developing a drug for the treatment of epilepsy; Lithera is developing aesthetic medicine products, including products for fat tissue reduction; and Regado is developing anticoagulants for use in treating heart disease.
Top NewsWednesday, December 19, 2012
Domain Associates, Rusnano Boost Three Firms By $93M